A gene expression-based immune signature for lung adenocarcinoma prognosis.

ABSTRACT:

Background

Lung adenocarcinoma (LUAD) has become the most frequent histologic type of lung cancer in the past several decades. Recent successes with immune checkpoint blockade therapy have demonstrated that the manipulation of the immune system is a very potent treatment for LUAD. This study aims to explore the role of immune-related genes in the development of LUAD and establish a signature that can predict overall survival for LUAD patients.

Methods

To identify the differential expression genes (DEGs) between normal and tumor tissues, we developed an analysis strategy to combine an independent-sample design and a paired-sample design using RNA-seq transcriptomic profiling data of The Cancer Genome Atlas LUAD samples. Further, we selected prognostic markers from DEGs and ev

SUBMITTER: Wang L 

PROVIDER: S-EPMC11027606 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature